Cassava Sciences | PTIE - Operating Profit


Cassava Sciences reported $-13.55M in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
Abbott USD 1.85B 399M Mar/2026
Amgen USD 3.83B 130M Mar/2026
Biogen USD 514.3M 128.8M Mar/2026
Cara Therapeutics USD -5.94M 3.55M Sep/2025
Cassava Sciences USD -13.55M 1.69M Dec/2025
Eisai JPY -10.31B 30.35B Mar/2026
Eli Lilly USD 9.78B 792M Mar/2026
Geron USD -236K 10.55M Mar/2026
J&J USD 6.62B 1.03B Mar/2026
Merck USD -1.88B 8.12B Mar/2026
Novartis USD 4.24B 171M Mar/2026
Novavax USD 20.94M 100.32M Dec/2025
Pfizer USD 4.99B 340M Mar/2026
Roche Holding CHF 9.56B 3.8B Dec/2025